ASSESSING IN VITRO ANTIMICROBIAL AND ANTIFUNGAL ACTIVITY FOR MEDICINAL PREPARATION ELGINA® VAGINAL TABLETS



Cite item

Full Text

Abstract

SCIENTIC RELEVANCE. Vaginal infections such as bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) are major women's health problems affecting millions of women worldwide. Moreover, in recent years, mixed infections with more severe and prolonged course and tending to recur have become a landmark for infectious and inflammatory gynaecological conditions. In some cases, this is due to the formation of polymicrobial biofilms, which contributes to higher microbial survival and lower effectiveness of monotherapy. To improve patient adherence in mixed infections, modern approaches aim to apply combination drugs for intravaginal use to achieve a high local concentration of the drug, while minimizing systemic absorption. The use of combined preparations, such as Elgina® vaginal tablets (WERTEKS JSC, Russia) containing several active substances with a wide spectrum of action provides an optimal solution. Investigating Elgina® antimicrobial and antifungal activity may profoundly contribute to current treatment practices of vaginal infections, improving clinical outcomes and reducing recurrence risk.

AIM. Evaluation of in vitro Elgina® preparation-related antimicrobial activity against bacterial vaginosis pathogens, including biofilm type, and antifungal activity against vulvovaginal candidiasis pathogens.

MATERIALS AND METHODS. Elgina® preparation-related antimicrobial activity against anaerobic and facultative anaerobic microorganisms (Atopobium vaginae (currently Fannyhessea vaginae), Gardnerella vaginalis, Bacteroides fragilis) was assessed using dilution in agar method by quantitating the minimum inhibitory concentration (MIC).

Antifungal activity against yeast-like fungi (Candida albicans, Candida glabrata) was performed analyzed by broth dilution method quantitating the minimum inhibitory concentration (MIC).

RESULTS. Elgina® has demonstrated high antimicrobial activity against the biofilm-forming microorganisms Bacteroides fragilis, Gardnerella vaginalis and Atopobium vaginae (now Fannyhessea vaginae), as well as antifungal activity against Candida albicans and Candida glabrata.

CONCLUSIONS. The data obtained show that Elgina® exerts a prominent antimicrobial activity against main pathogens causing vaginal infections such as BV, including biofilm type, and VVC. Elgina® is a more effective alternative to existing drugs on the pharmaceutical market.

About the authors

Kristina E. Borovkova

Research-and-manufacturing company «HOME ОF PHARMACY», Leningrad region, Russia

Email: borovkova.ke@doclinika.ru
ORCID iD: 0000-0003-1571-6549

head of microbiological laboratory

Russian Federation

Natalia V. Marchenko

WERTEKS JSC, Saint Petersburg, Russia

Email: NMarchenko@vertex.spb.ru
ORCID iD: 0000-0002-8869-8604

associate professor, candidate of pharmaceutical sciences, deputy director for product portfolio

Russian Federation

Svetlana A. Kopatko

WERTEKS JSC, Saint Petersburg, Russia

Email: SKopatko@vertex.spb.ru
ORCID iD: 0000-0003-2770-0130

deputy general director for product portfolio

Russian Federation

Dilara R. Kargopoltseva

WERTEKS JSC, Saint Petersburg, Russia

Author for correspondence.
Email: DKargopoltseva@vertex.spb.ru
ORCID iD: 0000-0002-9944-5223

leading pharmacologist

Russian Federation

References

  1. Галкин Д.В., Кречикова О.И., Сухорукова М.В., Дехнич А.В. Современные возможности терапии анаэробных инфекций // Клиническая микробиология и антимикробная химиотерапия. 2006. Т. 8, № 4. С. 298–313.
  2. ГОСТ Р ИСО 16256-2015. Клинические лабораторные исследования и диагностические тест-системы in vitro. Референтный метод для тестирования активности in vitro антимикробных препаратов в отношении дрожжевых грибов, вызывающих инфекционные заболевания.
  3. Довлетханова Э.Р., Абакарова П.Р. Современные возможности диагностики и лечения вульвовагинального кандидоза (в помощь практикующему врачу) // Медицинский Совет. 2019. №13. С. 42–48.
  4. Инструкция по медицинскому применению лекарственного препарата Эльжина®.
  5. Кира Е.Ф., Роговская С.И., Артымук Н.В., Савичева А.М., Гущин А.Е., Румянцева Т.А., Иванова О.В. Результаты изучения эффективности и безопасности вагинального применения орнидазола при лечении бактериального вагиноза // Акушерство и гинекология. 2015. №8. С. 89–95.
  6. Место комбинированных препаратов в лечении вагинальных инфекций. XIX Всероссийский научно-образовательный форум «Мать и дитя» // Эффективная фармакотерапия. 2018. № 37. С. 28–34.
  7. Методы контроля. Биологические и микробиологические факторы. Определение чувствительности микроорганизмов к антибактериальным препаратам. Методические указания МУК 4.2.1890-04.
  8. Общая характеристика лекарственного препарата ОХЛП препарата Эльжина® таблетки вагинальные.
  9. Падейская Е.Н. 5-Нитроимидазолы – антимикробные препараты для лечения бактериальных и протозойных инфекций // Consilium medicum. 2004. Т. 6, № 1. С. 32–40.
  10. Прилепская В.Н., Кира Е.Ф., Аполихина И.А., Байрамова Г.Р., Гомберг М.А., Минкина Г.Н. Клинические рекомендации по диагностике и лечению заболеваний, сопровождающихся патологическими выделениями из половых путей женщин. Москва: Издательство РОАГ, 2019. 56 с.
  11. Хрянин А.А., Решетников О.В. Бактериальный вагиноз: новые перспективы в лечении // Медицинский совет. 2015. № 9. С. 26–33.
  12. Abastabar M., Shokohi T., Rouhi Kord R., Badali H., Hashemi S.J., Ghasemi Z., Ghojoghi A., Baghi N., Abdollahi M., Hosseinpoor S., Rahimi N., Seifi Z., Gholami S., Haghani I., Jabari M.R., Pagheh A. In vitro activity of econazole in comparison with three common antifungal agents against clinical Candida strains isolated from superficial infections. Curr. Med. Mycol., 2015, vol. 1, no. 4, pp.7–12. doi: 10.18869/acadpub.cmm.1.4.7
  13. Abbe C., Mitchell C.M. Bacterial vaginosis: a review of approaches to treatment and prevention. Front. Reprod. Health, 2023, vol. 5. doi: 10.3389/frph.2023.1100029
  14. Brook I., Wexler H.M., Goldstein E.J. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin. Microbiol. Rev., 2013, vol. 26, no. 3, pp. 526–546. doi: 10.1128/CMR.00086-12
  15. Castro J., Rosca A.S., Cools P., Vaneechoutte M., Cerca N. Gardnerella vaginalis enhances Atopobium vaginae viability in an in vitro model. Front. Cell. Infect. Microbiol., 2020, vol. 10, no. 83. doi: 10.3389/fcimb.2020.00083
  16. Chen X., Lu Y., Chen T., Li R. The female vaginal microbiome in health and bacterial vaginosis. Front. Cell. Infect. Microbiol., 2021, vol. 11. doi: 10.3389/fcimb.2021.631972
  17. CLSI. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard, 9th ed. CLSI document M11-A8. 2018.
  18. Jasemi S., Emaneini M., Ahmadinejad Z., Fazeli M.S., Sechi L.A., Sadeghpour Heravi F., Feizabadi M.M. Antibiotic resistance pattern of Bacteroides fragilis isolated from clinical and colorectal specimens. Ann. Clin. Microbiol. Antimicrob., 2021, vol. 20, no. 1:27. doi: 10.1186/s12941-021-00435-w
  19. Jones A. Bacterial vaginosis: a review of treatment, recurrence, and disparities. The Journal for Nurse Practitioners, 2019, vol. 15, no. 6, pp. 420 – 423. doi: 10.1016/j.nurpra.2019.03.010
  20. Khedkar R., Pajai S. Bacterial vaginosis: a comprehensive narrative on the etiology, clinical features, and management approach. Cureus, 2022, vol. 14, no. 11: e31314. doi: 10.7759/cureus.31314
  21. Lehtoranta L., Ala-Jaakkola R., Laitila A., Maukonen J. Healthy vaginal microbiota and influence of probiotics across the female life span. Front. Microbiol., 2022, vol. 13. doi: 10.3389/fmicb.2022.819958
  22. Ma X., Wang X., Ye S., Liu J., Yuan H., Wang N. Biofilm and pathogenic factor analysis of Gardnerella vaginalis associated with bacterial vaginosis in Northeast China. Front. Microbiol., 2022, vol. 13. doi: 10.3389/fmicb.2022.1033040
  23. Mondal A.S., Sharma R., Trivedi N. Bacterial vaginosis: a state of microbial dysbiosis. Medicine in Microecology, 2023, vol. 16. doi: 10.1016/j.medmic.2023.100082
  24. Nyirjesy P., Brookhart C., Lazenby G., Schwebke J., Sobel J.D. Vulvovaginal candidiasis: a review of the evidence for the 2021 centers for disease control and prevention of sexually transmitted infections treatment guidelines. Clin Infect Dis., 2022, vol. 74. doi: 10.1093/cid/ciab1057
  25. Petrina M.A.B, Cosentino L.A., Rabe L.K., Hillier S.L. Susceptibility of bacterial vaginosis (BV)-associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycin. Anaerobe, 2017, vol. 47, pp. 115–119. doi: 10.1016/j.anaerobe.2017.05.005
  26. Sobel J.D., Kapernick P.S., Zervos M., Reed B.D., Hooton T., Soper D., Wittes H. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am. J. Obstet. Gynecol., 2001, vol. 185, no. 2, pp. 363–369. doi: 10.1067/mob.2001.115116
  27. Sobel J.D., Subramanian C., Foxman B., Fairfax M., Gygax S.E. Mixed vaginitis – more than coinfection and with therapeutic implications. Curr. Infect. Dis. Rep., 2013, vol. 15, pp. 104–108. doi: 10.1007/s11908-013-0325-5
  28. Sobel J.D., Vempati Y.S. Bacterial vaginosis and vulvovaginal candidiasis pathophysiologic interrelationship. Microorganisms, 2024, vol. 12, no. 1: 108. doi: 10.3390/microorganisms12010108
  29. Sousa E.G., Felice A.G., Dominici F.V., Jaiswal A.K., Pedrosa M.L.C., Reis L.P., Gomes L.G.R., Azevedo V.A.d.C., Soares S.d.C. Unveiling Resistance and Virulence Mechanisms under Darwinian Positive Selection for Novel Drug Discovery for Gardnerella vaginalis. Venereology, 2024, vol. 3, no. 3, pp. 120–135. doi: 10.3390/venereology3030010
  30. Sousa L.G.V., Novak J., França A., Muzny C.A., Cerca N. Gardnerella vaginalis, Fannyhessea vaginae, and Prevotella bivia strongly influence each other's transcriptome in triple-species biofilms. Microb Ecol., 2024, vol. 87, no. 1: 117. doi: 10.1007/s00248-024-02433-9
  31. Sun Z., Ge X., Qiu B., Xiang Z., Jiang C., Wu J., Li Y. Vulvovaginal candidiasis and vaginal microflora interaction: Microflora changes and probiotic therapy. Front. Cell. Infect. Microbiol., 2023, vol. 13. doi: 10.3389/fcimb.2023.1123026
  32. Swidsinski A., Amann R., Guschin A., Swidsinski S., Loening-Baucke V., Mendling W., Sobel J.D., Lamont R.F., Vaneechoutte M., Baptista P.V., Bradshaw C.S., Kogan I.Y., Savicheva А.M., Mitrokhin O.V., Swidsinski N.W., Sukhikh G.T., Priputnevich T.V., Apolikhina I.A., Dörffel Y. Polymicrobial consortia in the pathogenesis of biofilm vaginosis visualized by FISH. Historic review outlining the basic principles of the polymicrobial infection theory. Microbes and Infection, 2024, vol. 26, no. 8: 105403. doi: 10.1016/j.micinf.2024.105403
  33. Tarracchini C., Lugli G.A., Mancabelli L., Milani C., Turroni F., Ventura M. Assessing the genomic variability of gardnerella vaginalis through comparative genomic analyses: evolutionary and ecological implications. Appl. Environ. Microbiol., 2020, vol. 87, no. 1: e02188-20. doi: 10.1128/AEM.02188-20
  34. Wang Y., Liu Z., Chen T. Vaginal microbiota: Potential targets for vulvovaginal candidiasis infection. Heliyon, 2024, vol. 10, no. 5: e27239. doi: 10.1016/j.heliyon.2024.e27239
  35. Wust J. Susceptibility of anaerobic bacteria to metronidazole, ornidazole, and tinidazole and routine susceptibility testing by standardized methods. Antimicrob. Agents. Chemother., 1977, vol. 11, no. 4., pp. 631-637. doi: 10.1128/AAC.11.4.631

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) Borovkova K.E., Marchenko N.V., Kopatko S.A., Kargopoltseva D.R.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.